Table 1 Demographic and clinical characteristics of RA patients included in the discovery and replication cohorts.

From: Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

 

Discovery Population All patients

Discovery Population Patients with erosive disease

Discovery Population Patients without erosive disease

P-value

Replication Population All patients

Replication Population Patients with erosive disease

Replication Population Patients without erosive disease

P-value

Demographic characteristics

(n = 816)

(n = 567)

(n = 249)

 

(n = 436)

(n = 307)

(n = 129)

 

Age (years)

59.32 ± 13.11

59.66 ± 12.47

58.95 ± 14.30

0.50

53.59 ± 12.84

53.63 ± 10.17

53.47 ± 13.30

0.90

Sex ratio (female/male)

3.74 (644/172)

4.4 (462/105)

2.71 (182/67)

0.007

2.06 (294/143)

2.13 (209/98)

1.87 (84/45)

0.55

Clinical assessment

Percentage of patients with RF positivity*

571 (70.58)

409 (72.52)

162 (66.12)

0.07

328 (77.72)

235 (78.33)

93 (76.23)

0.64

Percentage of ACPA-positive patients*

490 (72.80)

354 (74.21)

136 (69.39)

0.20

90 (58.06)

64 (58.72)

26 (61.91)

0.72

DAS28 at baseline

5.63 ± 2.40

5.57 ± 1.18

5.79 ± 4.17

0.41

5.24 ± 1.27

5.27 ± 1.23

5.16 ± 1.36

 

Disease follow-up (years)

18.30 ± 9.34

19.43 ± 9.00

17.80 ± 14.44

0.10

9.00 ± 9.87

9.17 ± 10.17

8.58 ± 9.09

 

Percentage of RA patients having erosive disease

567 (69.49)

567 (100.0)

0 (0.0)

—

307 (70.41)

307 (100.0)

0 (0.0)

—

Percentage of RA patients with biologic treatments

632 (77.45)

448 (79.01)

184 (73.90)

0.11

436 (100.00)

307 (100.0)

129 (100.0)

1.00

DMARDs

Methotrexate∂

603 (79.24)

415 (79.20)

188 (79.32)

0.97

314 (75.48)

226 (77.13)

88 (71.54)

0.23

First biological treatment

Infliximab (%)

271 (42.88)

221 (44.02)

50 (37.88)

0.25

106 (24.31)

79 (25.73)

27 (20.93)

0.29

Etanercept (%)

176 (27.85)

134 (26.69)

42 (32.30)

0.20

101 (23.16)

72 (23.45)

29 (22.48)

0.83

Adalimumab (%)

157 (24.84)

126 (25.10)

31 (23.85)

0.77

229 (52.52)

156 (50.81)

73 (56.59)

0.27

Golimumab (%)

11 (1.74)

7 (01.39)

4 (03.08)

0.19

—

—

—

—

Abatacep (%)

5 (0.79)

4 (00.80)

1 (00.77)

0.98

—

—

—

—

Tocilizumab (%)

4 (0.63)

2 (00.40)

2 (01.52)

0.14

—

—

—

—

Rituximab (%)

8 (1.27)

8 (01.59)

0 (00.00)

—

—

—

—

—

  1. Data are means ± standard deviation or n (%). Abbreviations: RF, rheumatoid factor; ACPA: anti-citrullinated protein antibodies; DAS28, disease activity score; DMARDs, disease-modifying anti-rheumatic drugs. P < 0.05 in bold.
  2. *RF and anti-CCP data were available in 809 and 673 RA patients in the discovery population, respectively.
  3. *RF and anti-CCP data were available in 564 and 477 RA patients with erosive disease in the discovery population, respectively.
  4. *RF and anti-CCP data were available in 245 and 196 RA patients without erosive disease in the discovery population, respectively
  5. *RF and anti-CCP data were available in 422 and 151 RA patients in the replication population, respectively.
  6. *RF and anti-CCP data were available in 300 and 109 RA patients with erosive disease in the replication population, respectively.
  7. *RF and anti-CCP data were available in 122 and 42 RA patients without erosive disease in the replication population, respectively.
  8. ∂Information about methotrexate treatment was available in 761 and 416 patients in the discovery and replication populations, respectively.
  9. ∂Information about methotrexate treatment was available in 524 and 293 patients with erosive disease in the discovery and replication populations, respectively.
  10. ∂Information about methotrexate treatment was available in 237 and 123 patients without erosive disease in the discovery and replication populations, respectively.
Back to article page